Other News To Note
PharmaMar SA, of Madrid, a subsidiary of Zeltia SA, said it completed enrollment in its Phase IIb study testing PM01183 vs. topotecan in resistant/refractory ovarian cancer. The open-label study is designed to confirm PM01183's activity in that indication.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter